Research

Hormonal

Incretin-based pharmacotherapies (GLP-1 and GIP/GLP-1 agonists) induce substantial weight loss (up to 20%) in obesity, which significantly reduces OSA severity and improves cardio-metabolic health outcomes more effectively than continuous positive airway pressure (CPAP) therapy.

If you have obesity-related sleep apnea, talk to your doctor about incretin-based medications (like semaglutide or tirzepatide). These drugs help you lose significant weight (often 15-20%) by regulating hormones that control hunger and digestion. This weight loss can reduce your sleep apnea severity and improve your heart health more effectively than CPAP alone. Be prepared for potential gastrointestinal side effects and understand that these medications are likely intended for long-term use to maintain results.

GoodSupportsHIGH confidence
Evidence suggests that these improvements exceed those that occur with device-based OSA therapies like continuous positive airway pressure which continue to be the first-line of therapy.
Ronald R. Grunstein et al. · SLEEP · 2023

Why this rating

Based on multiple Phase III RCTs (STEP 1-5, SURMOUNT-1) cited in the paper, though long-term OSA-specific data is still pending.

Source

Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?

Ronald R. Grunstein et al. · SLEEP · 2023

DOI 10.1093/sleep/zsad224

narrative_reviewCited 30×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →